Drug & intervention

retifanlimab

RxCUI 2632981

Clinical trials12
Recruiting3
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

12 shown
Retifanlimab and Ruxolitinib In Solid MalignanciesNCT07219576 · 2026-01-08
RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160 · 2024-01-04
RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 · 2023-12-05
RECRUITING
Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNCT07772245 · 2026-12-31
NOT_YET_RECRUITING
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)NCT06959537 · 2025-08-13
SUSPENDED
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )NCT06939036 · 2025-07-01
TERMINATED
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerNCT04205812 · 2020-09-11
COMPLETED
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)NCT04203511 · 2020-07-31
WITHDRAWN
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)NCT03920839 · 2019-07-15
WITHDRAWN
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)NCT03679767 · 2019-01-09
COMPLETED
Combination Study of SV-BR-1-GM With RetifanlimabNCT03328026 · 2018-03-16
COMPLETED
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)NCT02393248 · 2015-02-27
TERMINATED

Conditions being studied

Breast Cancer4Breast Cancer Metastatic2Breast Neoplasm2Metastatic Breast Cancer2Advanced and/or Metastatic Solid Tumors1Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma1Cholangiocarcinoma1End Stage Cancer1Endometrial Cancer1Gastric Cancer1HER2-addicted Breast Cancer1Locally Advanced Renal Cell Carcinoma1Locally Advanced Urothelial Cancer1Lung Cancer1Merkel Cell Carcinoma1Metastatic Clear-Cell Renal Cell Carcinoma1Metastatic Melanoma1Metastatic Non-small Cell Lung Cancer1Metastatic Nonsquamous Non-Small Cell Lung Cancer1Metastatic Squamous Non-Small Cell Lung Cancer1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.